GlobeNewswire

GENFIT signe un partenariat de recherche avec EVerZom pour faire progresser une technologie de médecine régénérative basée sur les exosomes dans l’ACLF
10/11/2025
Le candidat-médicament expérimental EViv d'EVerZom, développé pour le traitement de l'ACLF en utilisant sa plateforme propriétaire d'exosomes, représente une approche novatrice en matière de thérapies régénératives En [...]
GENFIT Presents Promising New Preclinical Data on NTZ/G1090N for the Treatment of ACLF at The Liver Meeting® 2025
10/11/2025
Preclinical studies demonstrated significant efficacy on systemic inflammation and organ function in ACLF disease models Safety data from Phase 1 on healthy volunteers and initial efficacy signals from ex-vivo [...]
GENFIT présente de nouvelles données précliniques prometteuses sur NTZ/G1090N dans le traitement de l’ACLF dans le cadre du Liver Meeting® 2025
10/11/2025
Des études précliniques ont démontré une efficacité significative sur l'inflammation systémique et le fonctionnement des organes dans des modèles pathologiques d'ACLF. Des données de sécurité issues de l’étude de Phase [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis
10/11/2025
The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomide In a pivotal PPMS study (FENtrepid), fenebrutinib [...]
BioVersys BV100 Phase 2b to be Conducted Via Wellcome Funded Trial Network
10/11/2025
TRIAL TO BE CONDUCTED BY ADVANCE-ID, A NATIONAL UNIVERSITY OF SINGAPORE LED TRIAL NETWORK, IN PARTNERSHIP WITH BIOVERSYS Ad hoc announcement pursuant to Art. 53 LR BASEL, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- [...]
AVITA Medical to Host Investor Webinar Briefing
09/11/2025
VALENCIA, Calif., Nov. 09, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders and prospective [...]
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
09/11/2025
DUBLIN and BRIDGEWATER, N.J., Nov. 09, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN), a company committed to advancing the science of cardiovascular care, today highlighted a new post hoc analysis of [...]
RadNet Reports Third Quarter Financial Results with Record Quarterly Revenue and Adjusted EBITDA¹ and Revises Upwards 2025 Financial Guidance Ranges
09/11/2025
Total Company Revenue increased 13.4% to $522.9 million in the third quarter of 2025 from $461.1 million in the third quarter of 2024; Revenue from the Digital Health reportable segment (inclusive of intersegment [...]
AHA 2025: Late-Breaking Data Reinforce the Prognostic Power of AI-Driven Heartflow Plaque Analysis as the Most Clinically Validated Framework for Coronary Risk Stratification
09/11/2025
Multicenter outcomes FISH&CHIPS study of nearly 8,000 patients confirms total plaque volume as a powerful independent predictor of long-term cardiovascular events NEW ORLEANS, Nov. 09, 2025 (GLOBE NEWSWIRE) -- [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum